Kytopen Corp

Kytopen Corp. specializes in advanced genome engineering platforms that enhance cell therapy manufacturing efficiency. Their innovative technology streamlines the delivery of genetic materials, significantly improving patient access to cutting-edge treatments. Kytopen Corp.

was founded in 2017 in Cambridge, US, focusing on genome engineering solutions. In April 2026, Kytopen Corp raised an undisclosed amount of series B funding led by Telegraph Hill Partners. The founders, Cullen Buie and Paulo Garcia, have backgrounds that contribute to the company's vision and Michael Chiu as CEO and Kevin Gutshall as CCO. Kytopen has completed a total of four deals to date.

Kytopen specializes in advanced genome engineering platforms designed to enhance patient access to innovative cell therapies. The company’s flagship product, Flowfect®, utilizes a unique combination of continuous fluid flow and electric fields to facilitate non-viral gene delivery, enabling efficient transfection of mRNA, DNA, and CRISPR Cas9 RNP into billions of cells within minutes. This technology is particularly beneficial during the discovery phase of drug development, addressing critical challenges in cell therapy manufacturing by allowing researchers to optimize transfection conditions for up to 96 samples simultaneously. Kytopen's offerings cater to a diverse client base including pharmaceutical companies, biotechnological firms, and academic research institutions, predominantly within North America and Europe.

The scalability of their platforms from small-volume applications to large-scale manufacturing positions Kytopen as a pivotal player in the biotechnology sector, contributing to the development of next-generation living medicines. Kytopen generates revenue primarily through its innovative biomanufacturing solutions, especially from its Flowfect® product line designed for high-throughput transfections. The company engages in direct B2B transactions with clients, including pharmaceutical organizations and research institutions, providing essential tools for drug discovery and process optimization. Pricing models for its products accommodate varying scales of operations, though specific figures are not disclosed.

By facilitating clients in overcoming gene delivery bottlenecks at the discovery stage, Kytopen fosters long-term partnerships that assist in the transition from research to commercial-scale production. Revenue streams may also include service agreements and technology access programs, reinforcing Kytopen’s role in advancing cell therapy solutions. The company plans to utilize the April 2026 funding to scale commercialization of its non-viral, continuous flow cellular engineering platform and accelerate adoption of its Flowfect® technology across bioprocessing and cell therapy applications.